Abstract Purpose: It has been suggested that interleukin-6 (IL-6) is a prognostic indicator for survival in patients with gastric carcinoma, but this has not been proved using survival analysis. In Asians, the -634G allele is associated with increased IL-6 production. The objective of this study was to evaluate the association between serum IL-6 levels, -634G/C polymorphism, and overall survival after resection for gastric carcinoma. Experimental Design: A total of 155 consecutive patients with gastric carcinoma were evaluated. Serum IL-6 levels were analyzed using an enzyme-linked immunoabsorbent assay. Genotype was determined by PCR and restriction fragment length polymorphism. Serum levels and survival were correlated with genotype and clinicopathologic factors. Results: Age and stage, but not -634G/C genotype, were associated with serum IL-6 levels.The median survival for patients with stage II or stage III gastric carcinoma was 1,418 days in patients with low (V13 pg/mL) versus 618 days in patients with high (>13 pg/mL) serum IL-6 levels (P = 0.038). Results of a multivariate analysis showed that serum IL-6 level of >13 pg/mL was a significant predictor of poor survival (hazard ratio, 1.77; 95% confidence interval, 1.07-2.92; P = 0.026).
Interleukin-6 (IL-6) is a pleiotropic cytokine that plays an important role in host immunity. It is produced by a variety of malignancies, and high serum IL-6 levels are associated with shorter survival in patients with hematologic malignancies, prostate cancer, and renal cell carcinoma (1 -3) . Production of IL-6 by gastric cancer cell lines has been reported (4, 5) , as has the increase in levels of IL-6 in serum and cancer tissue in gastric cancer patients compared with control subjects (5 -8) . Serum IL-6 level has also been noted to correlate with disease progression and recurrence in gastric cancer (5, 7) . Although previous studies have suggested that IL-6 plays a role in tumor progression and that serum IL-6 level can be used as a prognostic indicator (5 -7), most have used disease stage as a surrogate marker for survival (6, 7) . In the one study that evaluated serum IL-6 level and patient survival, the results did not identify IL-6 as an independent prognostic indicator (5) . Therefore, whether and how IL-6 can be used as a prognostic indicator for survival in gastric cancer is not clearly understood.
Circulating levels of IL-6 are mainly regulated at the level of expression (9) . Several polymorphisms in the IL-6 gene have been reported, some of which have been suggested to regulate its expression (10 -13) . The -174G/C single-nucleotide polymorphism (SNP) in the promoter region is the best studied. The G allele is associated with an increased inflammatory response in vivo and the occurrence/prognosis of various diseases, including cancer, Alzheimer's disease, atherosclerosis, cardiovascular disease, non -insulin-dependent diabetes mellitus, osteoporosis, and systemic onset juvenile chronic arthritis (10, 11, 14 -20) . In Asian populations, however, this SNP is very rare (21 -23 ) and a more common and important SNP at position -634 (C>G) in the promoter region has been reported (22) . The -634G allele has been associated with increased production and secretion of IL-6 by peripheral blood mononuclear cells in vitro (12) . It has also been reported as a risk factor for progression of diabetic nephropathy and for lung cancer in conjunction with asthma/atopy (12, 24) .
Although the -634G allele has been associated with increased production of IL-6 in vitro, its effect in healthy subjects and patients with gastric adenocarcinoma has not been studied. We hypothesize that in patients with gastric adenocarcinoma, the -634G allele is associated with higher serum levels of IL-6 and shorter survival compared with -634C allele. The objectives of this study were (a) to compare serum IL-6 levels between -634G and -634C alleles in healthy subjects and in patients with gastric adenocarcinoma and (b) to analyze the potential associations between serum IL-6 level, -634G/C polymorphism, and overall survival after surgical resection.
Materials and Methods
Patients and preparation of samples. This was a retrospective cohort study conducted at National Taiwan University Hospital. The study protocol was approved by the institutional review board, and informed consent was obtained from all subjects.
Between 1999 and 2002, a total of 194 patients with histologically confirmed gastric adenocarcinoma were diagnosed by the investigators. Patients who consented to blood collection and underwent surgical resection at National Taiwan University Hospital were considered eligible. A total of 155 consecutive eligible patients were evaluated, and their serum IL-6 level was correlated with genotype and pathologic stage. In the evaluation of the association between survival and serum IL-6 level and genotype, data for eight patients who underwent palliative resection were excluded. The surgical procedures included resection of the tumor and at least D1 lymphadenectomy. Chemotherapy or radiotherapy was given as an adjuvant or for recurrence at the discretion of the physicians. Histopathology was evaluated by independent pathologists who were blinded to the clinical details of the patients. Tumor node metastasis (TNM) stage was defined according to the sixth edition of American Joint Committee on Cancer staging system (25) . Patient outcome data were obtained from review of medical records and the Cancer Registry, Office of Medical Records at National Taiwan University Hospital. Two hundred and eleven healthy subjects who received a routine health check up during the same period and who consented to blood sampling were recruited as controls. Venous blood samples were collected from all subjects and controls. Serum was separated by centrifuge and stored at -80jC until use. Buffy coat was prepared by centrifugation of whole blood collected in tubes containing heparin and was stored at -80jC until use. Samples were coded for blind analysis.
IL-6-634 G/C and -174 G/C genotyping. Genotyping was done for all gastric cancer and control subjects. Genomic DNA was extracted from buffy coat using a genomic DNA purification kit (Puregene DNA Purification System, Gentra Systems) according to the manufacturer's instructions. DNA was stored at -30jC until analysis. The IL-6-174G/C polymorphism was determined by PCR followed by RFLP analysis (10) . The 299-bp PCR product was amplified using forward primer 5 ¶-TTGTCAAGACATGCCAAAGTGCT-3 ¶ and reverse primer 5 ¶-GCCTCA-GACATCTCCAGTCC-3 ¶ with Taq polymerase (Promega) in the presence of 1.5 mmol/L Mg 2+ . Cycling variables were denaturation at 95jC (30 s), annealing at 65jC (30 s) , and extension at 72jC (45 s) for 35 cycles with final extension at 72jC for 10 min. Digestion was done with NlaIII (New England Biolabs) at 37jC for 3 h. The PCR product is cleaved into three fragments of 227, 59, and 13 bp in the presence of the G allele. The PCR product is cleaved into four fragments of 118, 109, 59, and 13 bp in the presence of the C allele. The IL-6 -634G/C polymorphism was determined by PCR followed by RFLP analysis (26) . The 180-bp PCR product was amplified using forward primer 5 ¶-GAG-ACGCCTTGAAGTAACTG-3 ¶ and reverse primer 5 ¶-AACCAAAGATG-TTCTGAACTGA-3 ¶ with Taq polymerase (Promega) in the presence of 1.5 mmol/L Mg 2+ . Cycling variables were denaturation at 95jC (45 s), annealing at 60jC (45 s) , and extension at 72jC (60 s) for 35 cycles with final extension at 72jC for 10 min. Digestion was done with BsrBI (New England Biolabs) at 37jC for 3 h. The C allele has no BsrBI cleavage site, whereas the PCR product is cleaved into two fragments of 120 bp and 60 bp in the presence of the G allele.
Enzyme-linked immunoabsorbent assay for IL-6. Serum IL-6 level was measured in all gastric adenocarcinoma patients and 63 control subjects selected by -634 C/G status (31 CC, 23 GC, and 9 GG subjects). Serum IL-6 levels were analyzed with a highly sensitive ELISA using a sandwich technique (Quantikine human IL-6 immunoassay, R&D Systems).
Statistical analysis. Quantitative data were summarized as mean F SD. Categorical variables were reported as percentages. The Fisher exact test was used to compare proportions. Student's t test was used to compare continuous variables. The associations between genotype and serum IL-6 level with adjustment for clinical variables, including sex, age, and TNM stage, were evaluated using multiple linear regression. Overall survival was calculated from the date of surgery, and only deaths due to gastric cancer were considered. Data for patients who were alive at last follow-up or had died due to other causes were censored at the date of last follow-up or death. As there was no clinically defined cutoff point for serum IL-6 level, the median was used to divide the patients into two groups (low versus high serum IL-6 level). The survival curves were graphed using the Kaplan-Meier method. The log-rank test was used to compare the equality of curves. The Cox proportional hazard regression model was used to evaluate the effects of genotype of IL-6 gene and serum IL-6 level when clinical prognostic factors were adjusted. Prognostic factors for univariate analysis included age, sex, depth of invasion (T), lymph node invasion (N), distant metastasis (M), tumor size, genotype of IL-6 gene, and categories of serum IL-6 level. Statistical software was used (SAS 9.1, SAS Institute) for analysis. All tests were two-tailed, and differences were considered statistically significant if the P value was <0.05. The Reporting Recommendations for Tumor Marker Prognostic Studies criteria were used for reporting the results (27) .
Power of the study. The primary objective of this study was to evaluate serum IL-6 as a prognostic indicator of gastric cancer mortality. Assuming an a value of 0.05 and a baseline 5-year survival rate of 25% (28, 29) , 73 patients in each group would provide 79% to 98% power to detect a clinically relevant difference in the survival curves corresponding to hazard ratios between 1.81 and 2.71. The power estimation was done with statistical software (nQuery Advisor 4.0).
Results
Genotype distributions in controls and gastric cancer patients. The genotype distribution of -634 G/C was not significantly different between gastric carcinoma patients and controls (P = 0.469; Table 1 ). No significant deviations from HardyWeinberg equilibrium were noted in gastric cancer patients and controls (P = 0.670 and P = 0.657, respectively). All controls and patients had GG at the -174 position.
Serum IL-6 levels in controls and gastric cancer patients. The serum IL-6 levels of controls and gastric carcinoma patients stratified by stage and genotype are summarized in Table 2 . There were no significant differences in serum IL-6 levels between CC and GC/GG genotypes (P = 0.429) in subjects in the control group. Using the median IL-6 level in gastric cancer patients (13 pg/mL) as the cutoff point, a stepwise increase in the proportion of patients with high serum IL-6 levels was noted with advancing TNM stages (P trend < 0.001; Table 2 ).
The results of multiple linear regression analysis with natural logarithm of serum IL-6 level as the response variable is summarized in Table 3 . Age and TNM stage, but not CC versus GC/GG genotypes, were significantly associated with serum IL-6 levels.
Association between IL-6 genotype, serum level, and survival. The median follow-up was 28 months, at which point 90% of the patients had died or had been followed for >2 years. Follow-up treatments are summarized in Table 4 . There was no significant difference between the two groups. Compared with patients with low (V13 pg/mL) serum IL-6 levels, patients with high (>13 pg/mL) serum IL-6 levels had a significantly shorter overall survival (P < 0.001). There was no difference in overall survival between patients with CC and GC/GG genotypes (P = 0.176; Fig. 1, top) .
Cox regression analysis with adjustment for factors including sex, age (V60 years versus >60 years), tumor size (<8 cm versus z8 cm), depth of invasion (T0f1 versus beyond), lymph node metastasis (N0f1 versus beyond), presence of distant metastasis, and IL-6 gene genotype (GG/GC versus CC) is summarized in Table 5 . After multivariable adjustment, the hazard of death related to an IL-6 level of >13 pg/mL was 1.77 [95% confidence interval (95% CI), 1.07-2.92; P = 0.026], which was similar in magnitude to that of seven or more lymph nodes with cancer metastasis (N2 or N3; hazard ratio 1.72, 95% CI 1.06-2.79; P = 0.029).
Overall survival for stages II and III (IIIa and IIIb) disease was significantly shorter than in stages 0 and I and significantly longer than in stage IV. No significant difference in overall survival was noted between stage II and stage III disease (P = 0.263; Fig. 1, bottom) . The effectiveness of serum IL-6 as a prognostic indicator was analyzed in the 86 patients with stage II and stage III disease. Patients with high serum IL-6 levels had a significantly lower likelihood of overall survival when compared with those with low serum IL-6 levels (median survival, 618 and 1418 days, respectively; P = 0.038; Fig. 1, bottom) .
Discussion
To our knowledge, this is the first study that confirms the prognostic value of serum IL-6 level in gastric carcinoma with survival of patients as the outcome measure. The effect of the IL-6 gene SNP -634 C/G on serum IL-6 level and survival in gastric adenocarcinoma has also not been studied before.
Correa's hypothesis of gastric cancer progression suggests inflammation as the key driving force in tumor development (30) , and IL-6 as a proinflammatory cytokine has been implicated in tumor growth (4) . Expression of IL-6 and the IL-6 receptor has been noted in gastric cancer cell lines, and IL-6 may act as a paracrine growth factor (4, 5). IL-6 induces gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway (31) , and our previous studies also indicated that IL-6 may play a role in the angiogenesis of gastric carcinoma via modulation of vascular endothelial growth factor (32) . Collectively, these studies are consistent with our results and suggest that IL-6 is crucial in tumor development and progression and may be a potential target for future research in the treatment of gastric carcinoma.
The median IL-6 level (13 pg/mL) was used as the cutoff level for the primary Cox regression analysis. Other cutoff values were also analyzed (25th and 75th percentile and starting from 5 pg/mL with an incremental increase of 5 pg/mL) for their sensitivity in predicting death due to gastric cancer. The results showed that in both univariate and multivariate analyses, the median was the most effective cutoff with the highest hazard ratio. For example, the hazard ratios of death of the high versus low IL-6 group in univariate analysis using the 25th and 75th percentile (4.7 and 38.5 pg/mL) as the cutoff were 1.85 (95% CI, 1.03-3.33; P = 0.039) and 2.08 (95% CI, 1.27-3.43; P = 0.004), respectively. Therefore, post-hoc analysis of the data also supported the median as the most effective cutoff value of serum IL-6 level in predicting survival after resection for gastric cancer.
The most important finding of this study was that serum IL-6 level was more effective than TNM stage in predicting long versus short overall survival after resection for stage II and stage III diseases. In Taiwan and Western countries, gastric carcinoma Table 2 . IL-6 serum levels (pg/mL): comparison between TNM stages and -634 G/C genotypes is usually diagnosed at an advanced stage, after the tumor has penetrated submucosa and invaded the muscle layer (33 -35).
The 5-year survival rate after surgery is only 20% to 30% once the tumor has penetrated the submucosa (29) . Controversies remain as to whether perioperative or neoadjuvant chemotherapy improves survival. Although a survival benefit compared with surgery alone has been observed with perioperative epirubicin, cisplatin, and fluorouracil (33), neoadjuvant fluorouracil, doxorubicin, and methotrexate have been shown to be associated with a shorter median survival, although not significantly (34) . In those studies, as in the current study, f50% of patients were diagnosed at stage II or stage III. Our results revealed that these patients can be divided into low versus high serum IL-6 groups with significant differences in survival. We propose that whereas chemotherapy may improve survival in patients with high serum IL-6 level, its benefit in patients with low serum IL-6 level may be marginal and offset by adverse effects. Therefore, the conflicting results in previous studies might be partly attributed to heterogeneity in IL-6 status and survival of patients in different studies. Our results indicated that serum IL-6 level was more effective than TNM stage in predicting patients with shorter survival after resection for stage II and stage III disease and could be used to identify patients who would benefit from perioperative or neoadjuvant chemotherapy. Additional studies are necessary to address this point. It is worth noting that whereas survival differences in stages II, IIIa, and IIIb patients after gastrectomy have been reported by the National Cancer Data Base report of 50,169 gastric carcinoma cases diagnosed from 1985 to 1996 (28), there was no significant difference in survival among these stages in our patients. In addition to differences in sample size, an important explanation for the different results in this study is the adequacy of lymphadenectomy. As noted in the National Cancer Data Base report, surgical undertreatment was a problem in their series, as only 18% of patients had 15 or more lymph nodes analyzed, with inadequate (D0) lymphadenectomy and a high likelihood of residual regional lymph node disease and inadequate staging (28) . In comparison, our patients underwent at least D1 dissection and more than half underwent D2 dissection and had more lymph nodes analyzed (Table 4) . Data from the Surveillance, Epidemiology, and End Results cancer registries also document that lymphadenectomy is frequently inadequate and that adequate lymphadenectomy is associated with an improvement in survival (36 -40) . If D1 resection was mandated for all patients in the National Cancer Data Base series, the differences in survival among stages II, IIIa, and IIIb might become less significant because of improved survival due to more complete surgical treatment and the effect of stage migration. The longer median survivals in our patients compared with the National Cancer Data Base series in stage II (1,431 days versus <3 years), stage IIIA (1,156 days versus <2 years), and stage IIIb (836 days versus f1 year) also support this explanation.
Although serum IL-6 level has also been reported to correlate with stage (5 -7), it was not an independent predictor of survival in the only other study that evaluated patient survival (5) . Possible explanations for the discrepant results include differences in the relative importance of various prognostic factors across stages and differences in the proportion of stages in the study populations. Our results indicated that serum IL-6 level was more effective than stage in predicting survival in stages II and III patients, although no differences in survival were noted in patients with high or low serum IL-6 level in stages 0, I, and IV. Stages 0/I and IV represent the two extremes of the disease. Serum IL-6 level might be less important than stage in predicting survival in these patients, because the prognosis after resection is usually good in stages 0 and I and the risk of recurrence is high in stage IV after surgery (41 -43) . As in the previous study, more patients were diagnosed as stage I or stage IV (61% versus 44% in this study); thus, the study may not have been adequately powered to identify serum IL-6 level as an independent predictor of survival. Another possible explanation is the improvement in treatment and care that occurred during the time between the two studies, which made serum IL-6 level more important as a prognostic factor in our study. Tumor size of z8 cm has also been reported as an independent predictor of shorter survival after controlling for TNM status (44) . In our study, tumor size of z8 cm was significant in univariate analysis, but it was not significant after controlling for TNM status and serum IL-6 level. One explanation is that the effect of tumor size might be mostly attributed to TNM status and serum IL-6 level. It is also possible that because only 25 subjects (17%) of patients in our study had a tumor of z8 cm, it may not have been adequately powered to identify tumor size as an independent predictor of survival.
Polymorphisms in the promoter of IL-6 gene have been shown to affect transcription and expression (10, 13) . Fishman et al. have shown that the IL-6 -174G allele is associated with increased expression and high levels of IL-6 (10). Terry and colleagues have reported that other promoter polymorphisms of IL-6 might also influence IL-6 expression (13). It is noteworthy that ethnic variations of SNPs and cytokine expression exist. In the Asian populations, the -634 G allele has been found to increase production/secretion of IL-6 in vitro and is associated with diabetic nephropathy and lung cancer (12, 24) . One of the objectives of the present study was to investigate the potential influence of the -634 G allele on serum IL-6 level and survival. Our results showed no differences in serum level and survival between patients with and without the -634 G allele and suggested that the effect of this SNP on IL-6 expression was limited. In our subjects, we also assessed the most well-studied SNP -174 G/C and detected no polymorphism at this position, which was consistent with prior studies (21 -23) . Additional studies are needed to identify functional polymorphisms of IL-6 in Asian populations.
In this study, treatment for gastric cancer was comparable between patients with low and high serum IL-6 levels ( Table 4) . Only 7 (4.8%) of the patients underwent adjuvant chemotherapy. Whereas the Southwest Oncology Group study (SWOG-9008) which was published at the late phase of our enrollment period showed a survival benefit for adjuvant chemoradiotherapy and concluded that it should be considered for patients at high risk for recurrence after resection (45) , adjuvant chemotherapy did not confer survival benefit in other studies (46, 47) . In the SWOG-9008 trial, 54% of patients underwent inadequate lymphadenectomy (D0 resection), and further analysis by the same authors showed that surgical undertreatment in this trial undermined survival (37) . Therefore, the value of adjuvant chemotherapy or chemoradiotherapy in patients undergoing adequate lymphadenectomy as in our patients may require further study. A limitation in this study was that the time to recurrence could not be determined with appropriate precision in some cases; thus, the relationship between various factors and disease-free survival could not be analyzed. Another limitation was that serum samples after surgical resection were not available, so the usefulness of serum IL-6 level for detecting recurrence after resection could not be evaluated. Whereas it may be inferred that serum IL-6 level may also be associated with recurrence and disease-free survival, additional studies are needed to address this point. Further study to investigate and validate the usefulness of serum IL-6 level in predicting prognosis and guiding treatment strategy will be conducted in a prospective cohort of gastric carcinoma patients.
In summary, the results of this study indicate that a serum IL-6 level of >13 pg/mL correlates positively with tumor progression and is an independent predictor of poor survival after resection. In stages II and III diseases, it is more effective than TNM stage as a prognostic factor. The -634G/C polymorphism is not associated with serum IL-6 level or survival in gastric carcinoma. As >50% of patients who undergo surgery are diagnosed at these stages in Taiwan and Western countries, serum IL-6 level is an important predictor of survival and may influence treatment strategy and subsequent patient outcome. Additional studies are needed to investigate the optimal treatment strategies, taking into account serum IL-6 levels. 
